JP2018538335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538335A5 JP2018538335A5 JP2018532639A JP2018532639A JP2018538335A5 JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5 JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf15
- therapeutic agent
- seq
- conjugate
- hgdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270967P | 2015-12-22 | 2015-12-22 | |
| US62/270,967 | 2015-12-22 | ||
| PCT/IB2016/057839 WO2017109706A1 (en) | 2015-12-22 | 2016-12-20 | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538335A JP2018538335A (ja) | 2018-12-27 |
| JP2018538335A5 true JP2018538335A5 (cg-RX-API-DMAC10.html) | 2020-01-30 |
| JP6946304B2 JP6946304B2 (ja) | 2021-10-06 |
Family
ID=57796765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532639A Expired - Fee Related JP6946304B2 (ja) | 2015-12-22 | 2016-12-20 | 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190000923A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3393494A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6946304B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN108367053A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017109706A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| JP6704358B2 (ja) | 2014-07-30 | 2020-06-03 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | 代謝障害を治療するための組成物および使用方法 |
| US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
| CN106687128B (zh) | 2014-10-31 | 2022-05-10 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| JP7296728B2 (ja) * | 2015-10-23 | 2023-06-23 | メルス ナムローゼ フェンノートシャップ | 癌の成長を抑制する結合分子 |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| EP3538124A4 (en) * | 2016-11-13 | 2020-07-22 | Imagine Pharma | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
| JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー/エス | 肥満の治療において使用するためのmic−1およびglp−1 |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| US12054527B2 (en) * | 2018-04-09 | 2024-08-06 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| WO2020009740A2 (en) * | 2018-04-25 | 2020-01-09 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| EP3833974A2 (en) | 2018-08-10 | 2021-06-16 | Novartis AG | Gfral extracellular domains and methods of use |
| MY205905A (en) | 2018-10-22 | 2024-11-20 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof |
| CN113474363A (zh) * | 2018-11-20 | 2021-10-01 | 詹森药业有限公司 | 用于降低体重和/或减少食物摄取量的gdf15类似物和方法 |
| US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| BR112021021271A2 (pt) * | 2019-04-23 | 2021-12-21 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo região fc de imunoglobulina e gdf15 |
| ES3061099T3 (en) | 2019-10-04 | 2026-03-31 | Amgen Inc | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| EP4081241A4 (en) * | 2019-12-24 | 2024-05-01 | Juvena Therapeutics, Inc. | REGENERATIVE POLYPEPTIDES AND USES THEREOF |
| WO2021136223A1 (en) | 2019-12-31 | 2021-07-08 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| CN113366024B (zh) * | 2020-01-08 | 2024-11-05 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| CN111333505B (zh) * | 2020-03-31 | 2022-07-26 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| EP4237438A4 (en) | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| KR102569644B1 (ko) * | 2020-10-30 | 2023-08-23 | 가톨릭대학교 산학협력단 | Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4351627A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST |
| AU2022278933A1 (en) * | 2021-05-21 | 2023-12-07 | Yuhan Corporation | Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのglp1受容体の活性化因子としての2-((4-((s)-2-(4-クロロ-2-フルオロフェニル)-2-メチルベンゾ[d][1,3]ジオキソール-4-イル)ピペリジン-1-イル)メチル)-1-(((s)-オキセタン-2-イル)メチル)-1h-イミダゾール誘導体 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| JP2024058473A (ja) * | 2022-10-14 | 2024-04-25 | 国立大学法人九州大学 | 筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの発現抑制剤、線維症治療用医薬組成物、並びに、in vitroで筋線維芽細胞のα-平滑筋アクチン及びコラーゲンの産生を抑制する方法 |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| CN118995820A (zh) * | 2024-10-22 | 2024-11-22 | 江苏凯基生物技术股份有限公司 | 一种生长分化因子-15及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| ATE423788T1 (de) | 1995-06-22 | 2009-03-15 | St Vincents Hosp Sydney | Neues tgf-beta-ahnliches cytokin |
| WO1998019523A1 (fr) * | 1996-11-01 | 1998-05-14 | Shionogi & Co., Ltd. | Souris modele pour maladies affectant l'homme |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2464532T3 (es) | 2001-04-19 | 2014-06-03 | The Scripps Research Institute | Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| US20030138417A1 (en) | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AR044399A1 (es) | 2003-05-20 | 2005-09-14 | Novartis Ag | Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN102816241B (zh) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | 清蛋白融合蛋白 |
| US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| CA2722829A1 (en) * | 2008-05-06 | 2009-11-12 | F. Hoffmann-La Roche Ag | Animal model for diabetes |
| JP5542832B2 (ja) | 2008-10-24 | 2014-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2012106615A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| JP5977814B2 (ja) * | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
| CA2848711C (en) * | 2011-09-16 | 2019-08-06 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| KR20140125803A (ko) * | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| JP6254146B2 (ja) * | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| CA2899170C (en) * | 2013-01-30 | 2022-08-02 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
| LT3027642T (lt) | 2013-07-31 | 2020-10-12 | Amgen Inc. | Augimo ir diferenciacijos faktoriaus 15(gdf-15) konstruktai |
| CA2952032C (en) * | 2014-06-20 | 2023-03-14 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| CN106573955B (zh) | 2014-06-23 | 2021-02-26 | 诺华股份有限公司 | 位点特异性蛋白质修饰 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2015197446A1 (en) | 2014-06-24 | 2015-12-30 | Novo Nordisk A/S | Mic-1 fusion proteins and uses thereof |
| WO2016102580A1 (en) | 2014-12-22 | 2016-06-30 | Novo Nordisk A/S | Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof |
-
2016
- 2016-12-20 US US16/064,054 patent/US20190000923A1/en not_active Abandoned
- 2016-12-20 WO PCT/IB2016/057839 patent/WO2017109706A1/en not_active Ceased
- 2016-12-20 JP JP2018532639A patent/JP6946304B2/ja not_active Expired - Fee Related
- 2016-12-20 EP EP16826174.1A patent/EP3393494A1/en not_active Withdrawn
- 2016-12-20 CN CN201680075098.4A patent/CN108367053A/zh active Pending
-
2022
- 2022-04-14 US US17/720,555 patent/US20220249614A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370262B2 (en) | Messenger RNA vaccines and uses thereof | |
| JP5185813B2 (ja) | 癌免疫治療のための組成物および方法 | |
| TWI685347B (zh) | 用於在活體中遞送RNAi觸發子至腫瘤細胞之聚結合物 | |
| CN103491982B (zh) | 具有酶敏感性连接的多核苷酸体内递送偶联物 | |
| JP2011530599A5 (cg-RX-API-DMAC10.html) | ||
| JP2016535009A5 (cg-RX-API-DMAC10.html) | ||
| JP2026510392A (ja) | 遺伝子編集においてならびにワクチン及び治療剤として使用するためのコードrna分子を含む脂質ナノ粒子 | |
| JP2019533707A (ja) | Mrna担持脂質ナノ粒子を調製する改善されたプロセス | |
| WO2007030375A3 (en) | Lysosomal acid lipase therapy for nafld and related diseases | |
| US9399016B2 (en) | Materials and complexes for the delivery of biologically-active materials to cells | |
| EP4171574A1 (en) | Compositions and methods for inducing an immune response against coronavirus | |
| ES2981281T3 (es) | Composiciones y métodos para modificar la superficie de las células y métodos de uso | |
| ES2220451T3 (es) | Tratamiento de una infeccion intracelular. | |
| US20200397848A1 (en) | Method of treating a liver disease comprising administering ostreolysin orfunctionally related variant thereof | |
| WO2025128871A2 (en) | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents | |
| AU2019381809B2 (en) | Compositions and uses of vasoactive intestinal peptide (VIP) antagonists | |
| US20240390483A1 (en) | Mucosal messenger rna vaccine | |
| WO2008075706A1 (ja) | 間質性肺炎治療剤 | |
| EP4651943A1 (en) | Lipidoid compounds and related compositions and uses | |
| CN101119743B (zh) | 免疫增强剂 | |
| Kang | Strategies to Design and Refine Lipid Nanoparticles for Functional mRNA Delivery | |
| HK1188947A (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | |
| HK1188947B (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |